

Curriculum Vitae

Personal information

Mattias Andersson

Work experience

Drug Product Specialist	Oasmia/Vivesto	2020–2024
Senior Formulation Scientist	Recipharm	2019–2020
Senior consultant, Owner	Galenometrics AB	2015–2023
Independent consultant	Disruptive Materials	2016–2017
Formulation expert, Consultant	Medivir	2014–2019
Owner & Founder, Galenometrics		2014
Research Scientist/Product Developer	Orexo	2007–2014
Drug Delivery & Innovations/Pharmaceutical Innovation & Development		
Research Scientist/CMC Project coordinator	Biolipox	2005–2007
Pharmaceutical Development		
Teacher	Umeå University	2001–2010
Department of Ecology and Environmental Science		
1 st laboratory engineer/Senior Scientist	Astra/AstraZeneca	1998–2005
Liquids/Product Development/Experimental Formulation		
1 st laboratory engineer Liquids/Preformulation/Lipid Drug Delivery	Pharmacia/ Pharmacia & Upjohn	1994–1998

Education and training

M.Sc, Chemical Engineering	Royal Institute of Technology, Stockholm - 1993
Statistical Learning	Stanford University - 2016
Pharmaceutical Bioinformatics, 7.5+10c	University of Uppsala - 2014
Fungal Toxicology, 7.5c	University of Umeå - 2000
Industrial Pharmacy, 7.5c	University of Uppsala -1996
Chemometrics, 15c	University of Stockholm -1994

Additional information

Publications

Andersson, M., Chajara, K., Sohlberg, R., Paesh, S., Wilkinson, K. & Demmer, C. Solubilizing compounds. (2024). PCT Int. Appl. WO2024068553

Andersson, M. (2020) Caloscypha fulgens (Ascomycota, Caloscyphaceae) – *distribution and phenological patterns in Scandinavia over*

the last 60 years. *Svensk Mykologisk Tidskrift* 41(3): 42–53

Andersson, M., Zacché, M. (2019). The advantages of 'Quality by Design' approach in pharma drug development. *Pharma Manufacturing*. 1-6.

Andersson, M. Nucleotide Phosphoramidate Formulation. (2018). US Patent App. 15/555,414

Glover, D., Amoozgar, Z., Garg, A.D., Baker, M., Boyle, D., Andersson, M., Dharmasiri, U., Pomerants, P., Petrak, K. Sexton-Radek, K. & Guang Wang, G. (2016). Top 5 trends in Immuno-oncology. Convettit Foresight. Presentation. DOI: [10.13140/RG.2.2.28989.05609](https://doi.org/10.13140/RG.2.2.28989.05609)

Forsgren, J., Andersson, M., Nilsson, P., Mhrranyan, A. Mesoporous calcium carbonate as phase stabiliser of amorphous celecoxib – an approach to increase the bioavailability of poorly soluble pharmaceutical substances. *Advanced Healthcare Materials* 2:11 (2013) 1469-1476

Pelcman, B., Sanin, A., Nilsson, P., Kromann, H., Pereswetoff-Morath, L., Andersson, M., Horvath, K. New triazole compounds useful in the treatment of inflammation. PCT Int. Appl. (2008) WO2008135767

Andersson, M., Ringberg, A., Gustafsson, C. Multivariate methods in tablet formulation suitable for early drug development: Predictive models from a screening design of several linked responses. *Chemometrics & Intelligent Laboratory Systems* 87 (2007) 125-130

Andersson, M., Ringberg, A., Gustafsson, C. Experimental design and optimization of tablet formulation regarding tablet hardness and in-vitro drug release profile. Poster EUFEPS 7th European Congress of Pharmaceutical Sciences. Stockholm 21-23 Oct 2001.

Andersson, M., Andersson M., Eriksson, P. Novel formulations of a-2,4-disulfofenyl-N-tert-butylitron. PCT Int. Appl. (2001) WO2001089507

Andersson, M. Johansson, D., Li, P., Norrlind, B., Westgren, B. Method of preparing pharmaceutical composition of lipid particles comprising a protein. (2001) US Patent 6,306,433

Projects

Memberships

Other Relevant
Information